DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Mr. Carl A. Mongiovi
Vice President
Pharmatech
9530 Padgett Street – Suite 101
San Diego, CA 92126

DEC 9 2002

Categorization Notification

Regulations codified at 42 CFR 493.15 et. seq., implementing the Clinical Laboratory Improvement Amendments of 1988, require the Secretary to provide for the categorization of specific clinical laboratory test systems by the level of complexity. Based upon these regulations, the following commercially marketed test system or assay for the analyte is categorized below:

Test Systems: PHAMATECH AT HOME QUICK CUP PREGNANCY TEST
PHAMATECH CLEAR CHOICE PREGNANCY TEST

Analyte: URINE HCG BY VISUAL COLOR COMPARISON TESTS

Re: k993141/A002 Complexity: Waived

This complexity categorization is effective as of the date of this notification. This categorization will be reported on FDA's home page http://www.fda.gov/cdrh/clia. This categorization information may be provided to the user of the commercially marketed test system or assay as specified for the analyte indicated. This categorization will also be announced in a Federal Register Notice, which will provide opportunity for comment on the decision. FDA reserves the right to reevaluate and recategorize this test based upon the comments received in response to the Federal Register Notice. For questions regarding FDA's categorization procedure, contact Clara A. Sliva, Acting CLIA Coordinator, at (301) 827-0496 or email http://www.CLIA@CDRH.FDA.GOV.

Sincerely yours,

Steven Gutman

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health